Follicular unit excision (FUE) is an increasingly popular hair restoration technique. In many instances, it surpasses linear strip excision (LSE) surgery in terms of number of procedures and clinics dedicated to performing FUE. The rise in popularity relates primarily to a somewhat misguided perception that FUE produces less evidence of a surgical procedure having been performed. This is based on the fact that a linear scar is avoided. The procedure is easier to learn and "less invasive" as compared to LSE harvesting and requires less staff and capital expense. The FUE procedure is aggressively marketed often as "scarless surgery." This false statement, along with the ease of starting an FUE practice, has resulted in various ethical issues related to evaluation, methodology, and business practices. In this chapter, we discuss the ethical issues surrounding FUE hair restoration surgery and the examination of the mathematics of donor management as it relates to the ethical management of the FUE patient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-2207-3413 | DOI Listing |
Am J Reprod Immunol
January 2025
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, China.
Background: Alterations in lipid metabolism were reported to impact human fertility; however, there is limited evidence on the association of lipid metabolism with embryo implantation as well as the etiology of recurrent implantation failure (RIF), especially regarding arachidonic acid metabolism.
Methods: Experimental verification research (16 RIF patients and 30 control patients) based on GEO database analysis (24 RIF patients and 24 control patients). The methods in bioinformatics included differential gene screening, functional enrichment analysis, protein-protein interaction network, cluster analysis, weighted gene co-expression network analysis, and so forth.
Cochrane Database Syst Rev
January 2025
Institute of Education in Healthcare and Medical Sciences, University of Aberdeen, Aberdeen, UK.
Background: Gonadotropin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone (LH) surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth. We compared the benefits and risks of the different GnRHa protocols used.
Objectives: To evaluate the effectiveness and safety of different GnRHa protocols used as adjuncts to COH in women undergoing ART.
Int J Dermatol
January 2025
Department of Dermatology, Warsaw University of Medicine, Warsaw, Poland.
Background: Afro-textured hair exhibits distinct physicochemical properties with possible variations in measurable hair parameters. Standardized documentation of trichoscopic norms of afro-textured hair in indigenous Africans is notably lacking.
Methods: A cross-sectional study involving 122 South Africans of both genders of African ancestry (mean age 20.
Am J Surg Pathol
January 2025
Department of Pathology, University Hospital Henri Mondor, AP-HP, Créteil, France.
Lymphomas of T-follicular helper origin (T-follicular helper-cell lymphoma [TFHL]) are often accompanied by an expansion of B-immunoblasts, occasionally with Hodgkin/Reed-Sternberg-like (HRS-like) cells, making the differential diagnosis with classic Hodgkin lymphoma (CHL) difficult. We compared the morphologic, immunophenotypic, and molecular features of 15 TFHL and 12 CHL samples and discussed 4 challenging cases of uncertain diagnosis. Compared with CHL, TFHL disclosed more frequent sparing of subcortical sinuses, high-endothelium venule proliferation, dendritic cell meshwork expansion, T-cell atypia, and aberrant T-cell immunophenotype.
View Article and Find Full Text PDFAm J Med Genet C Semin Med Genet
January 2025
Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!